Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

PURPOSE: New treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés, Javier, Rugo, Hope S., Twelves, Chris, Awada, Ahmad, Perez, Edith A., Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, O’Shaughnessy, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938835/
https://www.ncbi.nlm.nih.gov/pubmed/27441152
http://dx.doi.org/10.1186/s40064-016-2446-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938835/
https://www.ncbi.nlm.nih.gov/pubmed/27441152
http://dx.doi.org/10.1186/s40064-016-2446-4

Ejemplares similares